Piper Sandler raised the firm’s price target on BioMarin (BMRN) to $126 from $122 and keeps an Overweight rating on the shares following a Q4 top- and bottom-line beat and FY25 guidance that infers meaningful upside to consensus. With Voxzogo still showing robust growth and the legacy ERT/Palynziq business with meaningful growth potential, the firm likes BioMarin’s chances at meeting or beating FY27 revenue guidance of over $4B. Coupling this with two meaningful pipeline updates this year, Piper thinks management continues to execute well across all aspects of the business.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin price target raised to $82 from $81 at Citi
- BioMarin Pharmaceutical: Hold Rating Amid Strong Performance and Decelerating Growth Prospects
- BioMarin Pharmaceutical’s Strong Financial Performance and Growth Prospects Justify Buy Rating
- BioMarin’s Record Growth and 2025 Outlook
- Closing Bell Movers: Carvana down 8% on earnings, Palantir extends decline